🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05098769
Recruiting Observational

A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.

NCT05098769 · tracked via the Priya Life Science China tracker
Sponsor
Shengjing Hospital
Phase
Observational
Started
2021-01-18
Last updated
2026-03-11

Condition(s) studied

Pulmonary Embolism and ThrombosisDeterioration, Clinical

Study summary

This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography Exclusion Criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shenjing Hospital of CHINA MEDICAL UNIVERSITY Shenyang Liaoning Recruiting

More Shengjing Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05098769 on ClinicalTrials.gov ↗ ← All trials in China